RT Journal Article
SR Electronic
T1 Serologic Responses to COVID-19 Vaccination in Children with History of Multisystem Inflammatory Syndrome (MIS-C)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.11.19.22282551
DO 10.1101/2022.11.19.22282551
A1 Perez, Maria A.
A1 Hsiao, Hui-Mien
A1 Chen, Xuemin
A1 Kunkel, Amber
A1 Baida, Nadine
A1 Hussaini, Laila
A1 Lu, Austin T.
A1 Kao, Carol M.
A1 Laham, Federico R.
A1 Hunstad, David A.
A1 Beltran, Yajira
A1 Hammett, Teresa A.
A1 Godfred-Cato, Shana
A1 Chahroudi, Ann
A1 Anderson, Evan J.
A1 Belay, Ermias
A1 Rostad, Christina A.
YR 2022
UL http://medrxiv.org/content/early/2022/11/20/2022.11.19.22282551.abstract
AB Understanding the serological responses to COVID-19 vaccination in children with history of MIS-C could inform vaccination recommendations. We prospectively enrolled five children hospitalized with MIS-C and measured SARS-CoV-2 binding IgG antibodies to spike protein variants longitudinally pre- and post-Pfizer-BioNTech BNT162b2 primary series COVID-19 vaccination. We found that SARS-CoV-2 variant cross-reactive IgG antibodies waned following acute MIS-C, but were significantly boosted with vaccination and maintained for at least 3 months. We then compared post-vaccination binding, pseudovirus neutralizing, and functional antibody-dependent cell-mediated cytotoxicity (ADCC) titers to the reference strain (Wuhan-hu-1) and Omicron variant (B.1.1.529) among previously healthy children (n=6) and children with history of MIS-C (n=5) or COVID-19 (n=5). Despite the breadth of binding antibodies elicited by vaccination in all three groups, pseudovirus neutralizing and ADCC titers were reduced to the Omicron variant. Vaccination after MIS-C or COVID-19 (hybrid immunity) conferred advantage in generating pseudovirus neutralizing and functional ADCC antibodies to Omicron.Competing Interest StatementE.J.A. has received personal fees from AbbVie, MedScape, Pfizer, and Sanofi-Pasteur for consulting, and his institution receives funds to conduct clinical research unrelated to this manuscript from MedImmune, Regeneron, PaxVax, Pfizer, GSK, Merck, Novavax, Sanofi-Pasteur, Janssen, and Micron. He also serves on a safety monitoring board for Sanofi-Pasteur and Kentucky BioProcessing, Inc. C.A.R. institution has received funds to conduct clinical research unrelated to this manuscript from the National Institutes of Health, BioFire Inc, GSK, MedImmune, Micron, Janssen, Merck, Moderna, Novavax, PaxVax, Pfizer, Regeneron, Sanofi-Pasteur. She is co-inventor of patented RSV vaccine technology unrelated to this manuscript, which has been licensed to Meissa Vaccines, Inc. Funding StatementThis work was funded by Emory University and Childrens Healthcare of Atlanta, and by the U.S. Centers for Disease Control and Prevention.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Following informed consent and assent, we prospectively enrolled hospitalized children who met the CDC case definition for MIS-C; children with PCR-confirmed symptomatic COVID-19; and healthy pediatric controls into a specimen collection protocol approved by the Institutional Review Board (IRB) at Emory University.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.